Professor Minna Kellomäki starts as Director of BioMediTech institute
Professor Minna Kellomäki from Tampere University of Technology (TUT) starts as the director of BioMediTech institute from the beginning of 2017. Professor Kellomäki who is also the Dean at the faculty of BioMedical Sciences and Engineering at TUT starting its operations in the beginning of the year 2017, has previously acted as the Vice Director of the institute. Professor Anne Kallioniemi from University of Tampere starts as the Vice Director of the institute.
BioMediTech researchers one of the three winners in Tampere3 innovation competition
Read more on UTA website
Identification of gene defects helps the treatment of prostate cancer
The current method of treating prostate cancer involves identifying gene defects, which could help with the diagnosis of cancer and the development of individualised cancer treatments for patients. Professor Tapio Visakorpi at BioMediTech, University of Tampere is studying the molecular biology of prostate cancer, with funding by the Academy of Finland. The goal is to obtain a holistic picture of the disease’s mechanisms and use those mechanisms as a basis for developing new treatments.
“Most of the prostate cancers diagnosed are relatively benign and don’t necessarily require active treatment. On the other hand, some prostate cancers are highly aggressive. A major problem from the treatment perspective is that once the disease has been diagnosed, the clinical course is difficult to predict reliably,” says Visakorpi.
“Recent genome studies have shown that even though prostate cancer initiates in a single cell of origin, several cancer cell subpopulations with different genome types emerge as the disease progresses. This is not a single disease; several mechanisms lead to the emergence of the disease. Therefore, it’s important to identify those genome defects in each patient that occur in all cancer cells, that is, the so-called truncal mutations, and target the treatment to them,” says Visakorpi. “This requires taking multiple samples from the patient. The processing of samples also needs to be improved to make them more suitable for molecular analysis than the current methods. We’ve developed a new processing method for cancerous tissue.”
Researchers develop DNA-based single-electron electronic devices
Researchers at BioMediTech (BMT) of the University of Tampere and the Nanoscience Center (NSC) of the University of Jyväskylä have demonstrated a method to fabricate electronic devices by using DNA. The DNA itself has no part in the electrical function, but acts as a scaffold for forming a linear, pearl-necklace-like nanostructure consisting of three gold nanoparticles. The research was funded by the Academy of Finland.
Electrical measurements carried out in this study demonstrated for the first time that these scalable fabrication methods based on DNA self-assembly can be efficiently utilised to fabricate single-electron devices that work at room temperature.
Read more on the Academy of Finland website.
New Tenure Track Researchers at BioMediTech
PhD Veikko Sariola has started as Assistant Professor (bio-MEMS in cell and tissue engineering) at BioMediTech (Tampere University of Technology) in August. Read more about his research from TUT website.
PhD Oommen P Oommen has started as Assistant Professor (Biomaterials for cell and tissue engineering) at BioMediTech (Tampere University of Technology 1 September, 2016.
PhD Jaan-Olle Adressoo has started as Associate Professor (cell and tissue engineering) at BioMediTech (University of Tampere) on 1 September, 2016
PhD Vesa Hytönen has started as Associate Professor (cell and molecular biology) at BioMediTech (University of Tampere) on 1 September, 2016. He has previously worked for us as University Instructor (Biotechnology).
PhD Susanna Miettinen will be starting as Associate Professor (cell and tissue engineering) on 1 January, 2017. She is currently working as a University Researcher and Group leader at BioMediTech/ University of Tampere.